profit from every $100 of sales.
$0$100
XTL Biopharmaceuticals
$1.60-2.44% today
-57.6% in 1 year
1-year low $1.531-year high $4.28
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What XTL Biopharmaceuticals sold, what it kept, and what it did with the cash.
Sales went from $0 in 2021 to $451,000 in 2024, with -$1.03 million of profit last year.
SalesProfit
XTL Biopharmaceuticals vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| XTL Biopharmaceuticals | No profit yet | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads XTL Biopharmaceuticals's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| 0 | 0 | 0 | 0 | |
| – | 0 | 0 | 0 | |
| -1 | -1 | -1 | -2 | |
| -1 | -1 | -2 | -1 | |
| 0 | -1 | -2 | -1 | |
| -0.04 | -0.20 | -0.30 | -0.30 | |
| – | – | – | 0.7% | |
| – | – | – | -481.6% | |
| – | – | – | -227.7% |
Balance sheet
| In millions of USD | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Total assets | 7 | 4 | 2 | 9 |
| Cash | 3 | 2 | 1 | 0 |
| Total debt | – | – | – | 0 |
| Total liabilities | 1 | 0 | 0 | 3 |
| 5 | 4 | 2 | 5 | |
| 6 | 5 | 5 | 7 | |
| -15.3% | -26.6% | -63.4% | -16.0% | |
| 8.2% | -33.7% | -80.3% | -18.9% |
Cash flow
| In millions of USD | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| -1 | -1 | -1 | -2 | |
| – | – | – | 0 | |
| -1 | -1 | -1 | -2 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 0 | 0 | 0 | 0 |
Valuation
- –
- –
- –
- 0.9×
- 8.7×
- –
- –
- -42.5%
- -26.1%
- 0.0%
Profitability
- 0.7%
- -481.6%
- -227.7%
- -206.2%
- -29.7%
- -13.1%
- -26.8%
- -12.0%
- -34.2%
- 21.7%
Growth
- –
- –
- −136.5%
- –
- +7.0%
Financial health
- -0.3×
- 0.03
- 1.6%
- -77.6×
- 0.61
- 0.61
- 0.05
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 16%of 946
Bottom 1%of 986
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Dec 29, 2025 | -0.36 | – | – |
| Jun 30, 2025 | 0.10 | – | – |
| Jan 1, 2025 | -0.04 | – | – |
| Dec 30, 2024 | -0.13 | – | – |
| Sep 26, 2024 | -0.07 | – | – |
| May 13, 2024 | 0.10 | – | – |
| Mar 27, 2024 | -0.14 | – | – |
| Nov 15, 2023 | -0.04 | – | – |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
23No pass
Benjamin Graham
49No pass
Philip Fisher
35No pass
Peter Lynch
50No pass
Joel Greenblatt
0No pass
Charlie Munger
27No pass
Terry Smith
29No pass
Questions about XTL Biopharmaceuticals
Is XTL Biopharmaceuticals a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the XTL Biopharmaceuticals AI analysis
What does XTL Biopharmaceuticals do?
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. It is in Biotechnology.
Does XTL Biopharmaceuticals pay a dividend?
No. XTL Biopharmaceuticals does not pay a dividend at the moment.
Is XTL Biopharmaceuticals stock halal?
Yes. XTL Biopharmaceuticals passes our halal screen: its business is permitted and its debt is 4% of its market value, under the 30% limit. How we check
How has XTL Biopharmaceuticals stock done over the past year?
Down 57.6% over the past twelve months, to $1.60. It traded between $1.53 and $4.28 and is 62.6% below its high.
Who are XTL Biopharmaceuticals's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with XTL Biopharmaceuticals's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.